<![CDATA[Targeting HIF-2 Alpha as a Novel Therapeutic Strategy]]>
Trending
- FDA approved a revolutionary cancer drug. Insurance wasn’t ready
- 2025/26 in review: Cancer Research UK drives major progress against cancer – Cancer Research UK
- Chemogenomic maps reveal a PRDX1-dependent iron–damage axis in the DNA damage response
- Immune pathway activation in gastric cancers with LINE-1 retrotransposon overexpression and homologous recombination deficiency
- Terminally ill Carlisle woman calls for council tax change
- B cells in cancer: functions, mechanisms and therapeutic advances
- AI cancer cures slowed by chip shortage, says UK’s biggest tech boss
- Design, synthesis, and biological evaluation of quinolin-2-one/thiazole hybrids as multi-targeted antiproliferative agents inducing caspase-dependent apoptosis

![<![CDATA[Targeting HIF-2 Alpha as a Novel Therapeutic Strategy]]> Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing](https://news.shareyourcancerstories.com/wp-content/uploads/2026/03/How-Rapid-Therapeutic-Evolution-Has-Complicated-RCC-Sequencing-768x432.png)